Figure 6From: CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemiaImpact of PBX3 expression levels on prognosis. (A) Kaplan-Meier curves of overall survival (OS) in AML with low versus high expression of PBX3 displaying no significant difference between these two groups of AML patients; (B) Cumulative incidence of relapse showing higher relapse rates in PBX3-overexpressing AML patients (P = 0.004).Back to article page